Generative AI

Molecular,Model,Of,Antibody
#Antibody engineering #Automation / robotics #Drug development #Generative AI

Antibody engineering after generative AI: Solving the validation bottleneck

Stacey Willard, Vice President of Marketing and Product Management at Nuclera, explores the validation bottleneck for antibody engineering and why generative AI may be the answer to this challenge.  Antibody engineering has developed a pronounced asymmetry. AI can now generate and rank antibody candidates at a pace that conventional experimental… Read More

#Exclusive Content

Therapeutic antibodies
#Absci #AI #AI / data analytics / healthtech / informatics #Antibody-based therapeutics #Biologics #Generative AI #Machine learning

How the next generation of AI is reshaping antibody drug discovery

This is the latest episode of the free DDW Narrated Podcast. The episode covers two articles written for DDW Volume 25, Issue 2, Spring 2024. The first article is called ‘Machine learning: developing next generation antibody therapeutics’. Ben Holland, CTO and Co-Founder of Antiverse, discusses how artificial intelligence and… Read More

#Featured Podcasts #Podcasts

#AI #Drug discovery #Electronic Lab Notebooks (ELN) #Generative AI #Large language model (LLM)

Why we need to talk about third-generation ELNs 

DDW Editor Reece Armstrong provides a sponsored interview with Rob Brown, PhD, Head of the scientific office at Sapio Sciences.  Electronic lab notebooks (ELNs) have served as essential tools in researchers’ arsenals for decades. But as technology has advanced and the demands of drug discovery and development have… Read More

#Exclusive Content

Robot holds up a pill
#AI #AI / data analytics / healthtech / informatics #Drug discovery #Generative AI

From knowledge to creation: keeping up with AI 

Generative AI is now rapidly disrupting entire industries and new technology breakthroughs are emerging at pace. As new iterations push the boundaries of deep research and insight generation, the implications for life sciences are both profound and uncertain. Reflecting on the rapid progression of GenAI, and its potential to… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Drug development #Drug discovery #Generative AI

From knowledge to creation: keeping up with AI 

Generative AI is now rapidly disrupting entire industries and new technology breakthroughs are emerging at pace. As new iterations push the boundaries of deep research and insight generation, the implications for life sciences are both profound and uncertain. Reflecting on the rapid progression of GenAI, and its potential to… Read More

#Exclusive Content

AI and genomics
#Artificial intelligence (AI) #Drug discovery #Generative AI

New generative AI tool halves research time, data​ suggests

​​Elsevier has launched ScienceDirect AI, a generative AI tool for researchers. It is designed to transform the way researchers work by enabling them to instantly extract, summarise and compare trusted insights from millions of full-text articles and book chapters on ScienceDirect, a platform for peer-reviewed research. Researchers engage with a… Read More

#News

#Artificial intelligence (AI) #Cellular imaging #Generative AI #Laboratory data #Machine learning

How AI and ML empower a new world of drug discovery

David Gosalvez, Head of Product Strategy and Zev Wisotsky, Senior Principle Marketing Manager for Biologics at Revvity Signals, highlight how three powerful AI and ML capabilities are driving lab innovation: enhancing data accessibility, enabling intelligent chemical reaction recommendations, and automating complex cellular imaging. Enhancing data accessibility with generative AI A… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Amazon Web Services (AWS) #Artificial intelligence (AI) #Drug development #Drug discovery #Generative AI

Last chance to register: Generative AI in drug discovery

In this webinar, discover how high-performance computing (HPC) and AI are being used to screen out potentially dangerous drugs, improve the identification of drug candidates, and develop new therapeutic compounds. It can take years, and cost billions, to get new drugs approved for clinical use, but technological… Read More

Webinar date:
Supported by Amazon Web Services and NVIDIA
#News

#AI / data analytics / healthtech / informatics #Amazon Web Services (AWS) #Artificial intelligence (AI) #Drug development #Drug discovery #Generative AI

Webinar covers the benefits of generative AI in drug discovery

In this webinar, discover how high-performance computing (HPC) and AI are being used to screen out potentially dangerous drugs, improve the identification of drug candidates, and develop new therapeutic compounds. It can take years, and cost billions, to get new drugs approved for clinical use, but technological… Read More

Webinar date:
Supported by Amazon Web Services and NVIDIA
#News

#Artificial intelligence (AI) #BenevolentAI #Generative AI #Xaira Therapeutics

An AI lesson from history

This time last year DDW was reflecting upon the drug discovery and development sector’s push towards artificial intelligence (AI), in particular generative AI and how it could inform research. Within that article included the news of BenevolentAI’s disappointing results of its Phase II clinical trial of… Read More

#Business & Investment #Exclusive Content

Molecules
#AI / data analytics / healthtech / informatics #Amazon Web Services (AWS) #Artificial intelligence (AI) #Drug development #Drug discovery #Generative AI

Learn about the benefits of generative AI in drug discovery

In this webinar, discover how high-performance computing (HPC) and AI are being used to screen out potentially dangerous drugs, improve the identification of drug candidates, and develop new therapeutic compounds. It can take years, and cost billions, to get new drugs approved for clinical use, but technological… Read More

Webinar date:
Supported by Amazon Web Services and NVIDIA
#News

#AI / data analytics / healthtech / informatics #Amazon Web Services (AWS) #Artificial intelligence (AI) #Drug development #Drug discovery #Generative AI

Webinar: The benefits of generative AI in drug discovery

In this webinar, discover how high-performance computing (HPC) and AI are being used to screen out potentially dangerous drugs, improve the identification of drug candidates, and develop new therapeutic compounds. It can take years, and cost billions, to get new drugs approved for clinical use, but technological… Read More

Webinar date:
Supported by Amazon Web Services and NVIDIA
#News

#AI / data analytics / healthtech / informatics #Amazon Web Services (AWS) #Artificial intelligence (AI) #Drug development #Drug discovery #Generative AI

Register now: The benefits of generative AI in drug discovery

In this webinar, discover how high-performance computing (HPC) and AI are being used to screen out potentially dangerous drugs, improve the identification of drug candidates, and develop new therapeutic compounds. It can take years, and cost billions, to get new drugs approved for clinical use, but technological… Read More

Webinar date:
Supported by Amazon Web Services and NVIDIA
#News

AI concept
#Artificial intelligence (AI) #Collaboration #Financing #Generative AI #Machine learning

AI-powered drug discovery continues to attract investment

Optimism around the potential role for artificial intelligence (AI) in drug discovery continues, with recent financial deals supporting its use in developing therapeutics for age-related diseases, GPCR-targeting antibodies, DUB-modulating compounds, and novel fusion proteins. AI simulation to advance therapeutics for age-related diseases Biotech Shift Bioscience… Read More

#Business & Investment #News

Respiratory system
#Artificial intelligence (AI) #Generative AI #Idiopathic pulmonary fibrosis #Insilico Medicine #Phase II trial

Positive Phase IIa results support AI-powered drug discovery

Insilico Medicine has shared positive preliminary results from its Phase IIa clinical trial evaluating ISM001-055, a first-in-class small molecule targeting TNIK (Traf2- and Nck-interacting kinase). The drug was designed utilising generative AI to treat idiopathic pulmonary fibrosis (IPF). The study met both its primary… Read More

#Editor's Choice #News

#Absci #Artificial intelligence (AI) #Collaboration #Generative AI #Oncology #The Memorial Sloan Kettering Cancer Center

Partners use generative AI to develop novel cancer therapeutics

The Memorial Sloan Kettering Cancer Center (MSK) will be collaborating with Absci Corporation to discover and develop novel cancer therapeutics using generative artificial intelligence (AI) for up to six programmes. Under the terms of the collaboration, Absci and MSK’s cancer research teams will co-develop therapeutics using… Read More

#Cancer Research #News